Table 1.
Demographic and medical characteristics of breakthrough cases receiving both the doses of Covaxin and Covishield
| Variable | Total (n = 274) | Covaxin (n = 35) | Covishield (n = 239) | p value |
|---|---|---|---|---|
| Age (median, IQR) | 47.0 (28.0) | 31.0 (20.0) | 48.0 (25) | 0.000* |
| Sex | ||||
| Male | 186 (67.9%) | 20 (57.1%) | 166 (69.5%) | 0.145 |
| Female | 88 (32.1%) | 15 (42.9%) | 73 (30.5%) | |
| Occupation | ||||
| HWCs | 40 (14.6%) | 15 (42.9%) | 25 (10.5%) | 0.000* |
| Non‐HWCs | 234 (85.4%) | 20 (57.1%) | 214 (89.5%) | |
| Duration of vaccination and RT‐PCR positivity (median, IQR) | 44.5 (36.0) | 33.0 (42.0) | 45.0 (36.0) | 0.318 |
| Symptomatic | ||||
| Yes | 228 (83.2%) | 29 (82.9%) | 199 (83.3%) | 0.952 |
| No | 46 (16.8%) | 6 (17.1%) | 40 (16.7%) | |
| Hospitalization | ||||
| Yes | 27 (9.9%) | 3 (8.6%) | 24 (10.0%) | 0.537 |
| No | 247 (90.1%) | 32 (91.4%) | 215 (90.0%) | |
| Duration of hospitalization (median, IQR) | 11.0 (6.0) | 12.0 (–) | 10.5 (7.0) | 0.533 |
| C t value (median, IQR) | 21.2 (7.0) | 21.0 (6.0) | 22.0 (7.0) | 0.812 |
| Antibody positive against S protein | ||||
| Yes | 258 (94.2%) | 27 (77.1%) | 231 (96.7) | 0.000* |
| No | 16 (5.8%) | 8 (22.9%) | 8 (3.3%) | |
| Antibody titer (median, IQR) | 564.4 (1516.4) | 213.5 (537.5) | 647.5 (1645.1) | 0.000* |
| Comorbidities | ||||
| Yes | 64 (23.4%) | 5 (14.3%) | 59 (24.7%) | 0.174 |
| No | 210 (76.6%) | 30 (85.7%) | 180 (75.3%) | |
Abbreviations: HWCs, healthcare workers; IQR, interquartile range; RT‐PCR, real time polymerase chain reaction.
*
p < 0.05